Skip to main content
Premium Trial:

Request an Annual Quote

Genes2Me Obtains CE Marking for Clinical Sequencing Panels

NEW YORK – Indian genetic testing company Genes2Me said on Wednesday that it has obtained CE marking for more than 25 next-generation sequencing-based panels for oncology, pharmacogenomics, and hereditary diseases.

The panels were designed and have been validated for all NGS platforms from Illumina, Thermo Fisher Scientific, and MGI and come with automated data analysis pipelines.

One of the company’s offerings is a pan-cancer panel that covers 525 genes. Starting with 50 ng of nucleic acid, the firm said, the panel can detect single nucleotide variants, insertions and deletions, copy number variants, microsatellite instability, fusions, splice variants, and oncogenic viruses, as well as measure tumor mutation burden in one assay.

In addition, the company offers liquid biopsy NGS panels for colon, breast, and lung cancer; pharmacogenomics panels that help with the selection and dosage of drugs; a clinical exome sequencing extended panel; and targeted panels for neuromuscular diseases, epilepsy, Alzheimer's disease, Parkinson's disease, and dementia.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.